SB 242 — Requires the Department of Health and Human Services to establish the Psychedelic Medicines Working Group. (BDR S-39)

EXEMPTSenate (ReprintedBill withNo. amendments adopted on April 21, 2023) FIRST REPRINT S.B.

242242–Senators SENATENguyen, BILLDonate; NO .

242–SENATORSFlores, NHansen, GUYEND. , DONATE ;

FLORESHarris, ,Ohrenschall Hand ANSENStone ,Joint D.Sponsors:

HARRIS,Assemblymen OHRENSCHALLCarter ANDand STONEMarzola MCHAPTER.......... ARCH 9, 2023 ____________ JOINT SPONSORS :

SSEMBLYMEN CARTER AND M ARZOLA ____________ Referred to Committee on Health and Human Services SUMMARY—Requires the Department of Health and Human Services to establish the Psychedelic Medicines Working Group.

(BDR S-39) FISCAL NOTE:

Effect on Local Government:

No.

Effect on the State:

Yes.

~ EXPLANATION – Matter in bolded italics is new;

matter between brackets [omitted material] is material to be omitted.

This bill requires the Department of Health and Human Services to establish the Psychedelic Medicines Working Group to study certain issues relating to the therapeutic“entheogen” useto ofinclude, entheogenswithout duringlimitation, thepsilocybin 2023-2024and interim.psilocin.

This bill defines “entheogen” to include, without limitation, psilocybin and psilocin.

the(1) Departmentprescribes of Health and Human Services to submit a written report describing the activities,membership findings, conclusions and recommendationsduties of the Working GroupGroup; for transmittal to the 83rd Session of the Legislature.

and (2) requires the Department of Health and Human Services to submit a written report describing the activities, findings, conclusions and recommendations of the Working Group for transmittal to the 83rd Session of the Legislature.

EXPLANATION – Matter in bolded italics is new;

matter between brackets [omitted material] is material to be omitted.

and W HEREAS , Studies conducted by nationally and internationally recognized medical institutions indicate that psilocybin has shown - *SB242_R1* – 2 – efficacy and safety in the treatment of a variety of behavioral health conditions, including, without limitation, addiction, treatment- resistant depression, major depressive disorder, post-traumatic stress disorder and psychological distress relating to the end of life;

now, therefore THE- PEOPLE82nd OFSession THE(2023) STATE– OF2 NEVADA,– REPRESENTEDTHE IN SENATE AND ASSEMBLY, DO ENACT AS FOLLOWS:FOLLOWS:D IN Sections 1-3.

Section 1.

2.

(Deleted by amendment.) Sec.

3.

(Deleted by amendment.) Sec.

and (i) The following members appointed by the Governor, each of whom must be a bona fide resident of this State for not less than 1 year immediatelyi(1) precedingOne hismember orwho herhas appointment:received an honorable discharge from the Armed Forces of the United States and who has experience with the use of entheogens to address post-traumatic stress disorder;

(1)(2) One member who hasis receiveda anpsychiatrist, honorableor dischargea frompsychologist thewith Armedclinical Forcesexperience, of the United States and whowho: has experience with the use of entheogens to address post-traumatic stress disorder;

- *SB242_R1* – 3 – (2) One member who is a psychiatrist, or a psychologist with clinical experience, and who:

and - 82nd Session (2023) – 3 – (7) One member who is a representative of a law enforcement agency in this State.

(a) Examine various entheogens to determine which entheogens may be beneficial for therapeutic use in reducing suicidal ideation and improving mental health, including, without limitation, through the use of entheogens in the treatment of post-traumatic stress disorder, substance use disorder, major depressive disorder or psychological distress relating to the end of life;

5.subcommittees composed of members of the public who have appoint relevant experience or knowledge to consider specific issues or other matters relating to the therapeutic use of entheogens.

The Chair of the Working Group may appoint subcommittees composed of members of the public who have - *SB242_R1* – 4 – relevant experience or knowledge to consider specific issues or other matters relating to the therapeutic use of entheogens.

and (b) While engaged in the business of the Working Group, is entitled to receive the per diem allowance and travel expenses provided for state officers and employees generally.

The Department of Health and Human Services shall, on or before December 31, 2024, prepare and submit a written report describing the activities, findings, conclusions and - 82nd Session (2023) – 4 – recommendations of the Working Group to the Director of the Legislative Counsel Bureau for transmittal to the 83rd Session of the Legislature.

H~~~~~ 23 - *SB242_R1*82nd Session (2023)